Federal Register / Vol. 87, No. 29 / Friday, February 11, 2022 / Notices 8023 

Date: March 15–16, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bo Hong, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6194, MSC 7804, Bethesda, MD 

20892, 301–996–6208, hongb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict—Lung Disorders. 

Date: March 15–16, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: George M. Barnas, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4220, 

MSC 7818, Bethesda, MD 20892, 301–435– 

0696, barnasg@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Anti-Infective Therapeutics. 

Date: March 15–16, 2022. 

Time: 9:30 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bidyottam Mittra, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20894, 301–435–4057, bidyottam.mittra@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Health 

Promotion in Communities: Vaccine 

Hesitancy. 

Date: March 15, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lisa Tisdale Wigfall, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1007G, 

Bethesda, MD 20892, (301) 594–5622, 

wigfalllt@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; The BloodBrain Barrier, Neurovascular Systems and 

CNS Therapeutics. 

Date: March 16, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Linda MacArthur, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4187, 

Bethesda, MD 20892, 301–537–9986, 

macarthurlh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Musculoskeletal, Rehabilitation 

and Skin Sciences. 

Date: March 16–17, 2022. 

Time: 10:00 a.m. to 10:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Carmen Bertoni, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805B, 

Bethesda, MD 20892, (301) 867–5309, 

bertonic2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Cardiovascular and Surgical 

Devices. 

Date: March 17–18, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Willard Wilson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive Bethesda, MD 

20817, 301–867–5309, willard.wilson@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

21–026: Tissue Mapping Centers for the 

Human BioMolecular Atlas Program (U54). 

Date: March 17–18, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Raj K. Krishnaraju, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

Bethesda, MD 20892, 301–435–1047, 

kkrishna@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Infectious, Foodborne and 

Waterborne Disease Diagnostics and Methods 

in Microbial Sterilization and Disinfection. 

Date: March 17–18, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Gagan Pandya, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, RM 3200, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

1167, pandyaga@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–20– 

117: Maximizing Investigators’ Research 

Award (MIRA) for Early Stage Investigators 

(R35—Clinical Trial Optional). 

Date: March 17–18, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kevin Czaplinski, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6901 Rockledge Drive, 

Bethesda, MD 20892, (301) 480–9139, 

czaplinskik2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 7, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–02903 Filed 2–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Request for Information (RFI): Inviting 

Comments and Suggestions on a 

Framework for the NIH-Wide Strategic 

Plan for Diversity, Equity, Inclusion, 

and Accessibility 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This Request for Information 

(RFI) is intended to gather broad public 

input to assist the National Institutes of 

Health (NIH) in developing the NIHWide Strategic Plan for Diversity, 

Equity, Inclusion, and Accessibility 

(DEIA). NIH invites input from 

stakeholders throughout the scientific 

research, advocacy, and clinical practice 

communities, as well as the general 

public, regarding the proposed 

framework for the NIH-Wide Strategic 

Plan for DEIA. Organizations are 

strongly encouraged to submit a single 

response that reflects the views of their 

organization and their membership as a 

whole. 

DATES: This RFI is open for public 

comment for a period of 60 days. 

Comments must be received by 11:59:59 

p.m. (ET) on April 3, 2022, to ensure 

consideration. 

ADDRESSES: All comments must be 

submitted electronically on the 

submission website available at https:// 

rfi.grants.nih.gov/?s=

61e9a09a971100006d005012. 


lotter on DSK11XQN23PROD with NOTICES1
8024 Federal Register / Vol. 87, No. 29 / Friday, February 11, 2022 / Notices 

FOR FURTHER INFORMATION CONTACT: 

Please direct all inquiries to: Marina 

Volkov, nihstrategicplan@od.nih.gov, 

301–496–4147. 

SUPPLEMENTARY INFORMATION: The 

purpose of the NIH-Wide Strategic Plan 

for DEIA is to articulate NIH’s vision for 

embracing, integrating, and 

strengthening DEIA across all NIH 

activities to achieve the NIH mission. 

The Strategic Plan will capture activities 

that NIH will undertake to meet the 

vision of the Strategic Plan, and will be 

organized around accomplishments, 

needs, opportunities, and challenges in 

addressing DEIA in the NIH internal and 

extramural workforce, its structure and 

culture, and the research it supports. 

NIH has implemented a range of other 

initiatives to advance DEIA. Among 

them, the UNITE initiative (https://

www.nih.gov/ending-structural-racism/ 

unite) was established in 2021 to 

identify and address structural racism 

within the NIH-supported and the 

greater scientific community. Please 

note that an RFI on the Draft 2022–2026 

Chief Officer for Scientific Workforce 

Diversity (COSWD) Strategic Plan 

(https://grants.nih.gov/grants/guide/ 

notice-files/NOT-OD-22-054.html) was 

released on January 12, 2022 and, 

therefore, is open for public comment at 

the same time as this Framework for the 

NIH-Wide Strategic Plan for DEIA. You 

are encouraged to respond to both. 

The NIH-Wide Strategic Plan for DEIA 

is being developed in part as a response 

to Report 116–450 on H.R. 7614: 

Diversity at NIH Working Group and 

Strategic Plan, and is responsive to 

Executive Order 14035 and the 

Government-Wide Strategic Plan to 

Advance Diversity, Equity, Inclusion, 

and Accessibility in the Federal 

Workforce (https://

www.whitehouse.gov/briefing-room/ 

presidential-actions/2021/06/25/ 

executive-order-on-diversity-equityinclusion-and-accessibility-in-thefederal-workforce/). 

The NIH-Wide Strategic Plan for DEIA 

will highlight NIH’s ongoing and future 

efforts to foster DEIA within the 

biomedical and health research 

enterprise. The Framework for the NIHWide Strategic Plan for DEIA, below, 

articulates NIH’s priorities in three key 

areas (Objectives): Organizational 

practices to center and prioritize DEIA 

within the workforce; broad efforts to 

manage and sustain DEIA through 

structural and cultural change; and 

research to promote both workforce and 

health equity. These Objectives apply 

across NIH. 

NIH-Wide Strategic Plan for DEIA 

Framework 

Objective 1: Implement Organizational 

Practices To Center and Prioritize DEIA 

in the Workforce 

• NIH Workforce 

• Workforce at Institutions Supported 

by NIH Funding 

Objective 2: Grow and Sustain DEIA 

Through Structural and Cultural 

Change 

• Stewardship 

• Partnerships and Engagements 

• Accountability and Confidence 

• Management and Operations 

Objective 3: Advance DEIA Through 

Research 

• Workforce Research 

• Health Research 

The NIH seeks comments on any or 

all of NIH’s priorities across the three 

key areas (Objectives) articulated in the 

framework, including potential benefits, 

drawbacks or challenges, and other 

priority areas for consideration. 

NIH encourages organizations (e.g., 

patient advocacy groups, professional 

organizations) to submit a single 

response reflective of the views of the 

organization or membership as a whole. 

Responses to this RFI are voluntary 

and may be submitted anonymously. 

Please do not include any personally 

identifiable information or any 

information that you do not wish to 

make public. Proprietary, classified, 

confidential, or sensitive information 

should not be included in your 

response. The Government will use the 

information submitted in response to 

this RFI at its discretion. The 

Government reserves the right to use 

any submitted information on public 

websites, in reports, in summaries of the 

state of the science, in any possible 

resultant solicitation(s), grant(s), or 

cooperative agreement(s), or in the 

development of future funding 

opportunity announcements. This RFI is 

for informational and for planning 

purposes only and is not a solicitation 

for applications or an obligation on the 

part of the Government to provide 

support for any ideas identified in 

response to it. Please note that the 

Government will not pay for the 

preparation of any information 

submitted or for use of that information. 

We look forward to your input and 

hope that you will share this RFI 

opportunity with your colleagues. 

Dated: February 7, 2022. 

Tara A. Schwetz, 

Acting Principal Deputy Director, National 

Institutes of Health. 

[FR Doc. 2022–02972 Filed 2–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; 

Immunometabolism and Aging. 

Date: February 23, 2022. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Video Meeting). 

Contact Person: Kimberly Firth, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, National 

Institutes of Health, Gateway Building, 7201 

Wisconsin Avenue, Suite 2W200, Bethesda, 

MD 20892, 301–402–7702, firthkm@

mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: February 7, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–02918 Filed 2–10–22; 8:45 am] 

BILLING CODE 4140–01–P 


lotter on DSK11XQN23PROD with NOTICES1